01-02-2023 | Infliximab | Case report
Golimumab/infliximab/secukinumab
Inflammatory bowel disease, allergy and lack of efficacy: 2 case reports
Published in: Reactions Weekly | Issue 1/2023
Login to get accessExcerpt
Author Information-
* death
-
* life-threatening
-
* hospitalisation
-
* disability
-
* congenital anomaly
-
* other medically important event